Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune, Oncology, Neurological, and Osteoporosis Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTK2B/PYK2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Active Kinase & Antigen | PTK2B Active Recombinant Protein / Kinase Domain & Full-Length Protein High purity (>95%), Auto-phosphorylation competent, Endotoxin <1EU/ug. Sequence Verified. |
View PTK2B Products |
| Mutant Panel | PTK2B Kinase Domain Mutants (Gatekeeper/Activation Loop) For resistance screening and selectivity profiling. |
View PTK2B Products |
| Gene Delivery | PTK2B Promise-ORF / Lentivirus Full-length ORF for stable cell lines. HEK293 expressed backbone. |
View PTK2B Products |
| Benchmark Ab | Anti-PTK2B (Sequence-verified / Monoclonal) Recombinant positive control for Western/IP/IHC/Flow. |
View PTK2B Products |
| Validator | PTK2B siRNA Set For knockdown verification and specificity checks. |
View PTK2B Products |
| PTK2 (FAK) | PTK2 (FAK) Paralog kinase - critical for selectivity screening and compensatory bypass pathway. |
View PTK2 Products |
| SRC | SRC Upstream activator of PYK2; critical for phosphorylation cascade assays. |
View SRC Products |
| BTK | BTK Parallel B-cell signaling pathway. |
View BTK Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| FAK vs PYK2 Selectivity (High homology in catalytic domain) | Human PYK2 & FAK Kinase Domains available as separate, sequence-verified proteins (>95% purity) for parallel screening. |
| Auto-phosphorylation Site Detection (Y402, Y579/580) | Active proteins with verified phosphorylation capability; Phospho-specific Ab controls available. |
| Allosteric Binding Site Validation | Full-length protein constructs including FERM domain available via Lentivirus expression. |
| Drug Resistance Profiling | Wild-Type and key mutant recombinant kinase domains; Endotoxin Controlled, Theoretical MW confirmed. |
| Cell-Based Degradation Assay | Lentivirus Premade Particles for stable PYK2-expression lines; cell-based assays preserve native conformation and signaling context. |
| False Positives | Validated siRNA included for specificity checks in cellular assays. |
Live PTK2B/PYK2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTK2B/PYK2 therapeutics is intensifying, with major players shifting focus from broad-spectrum kinase inhibitors to highly selective and allosteric modalities. As first-generation ATP-competitive inhibitors face selectivity challenges against the paralog FAK (PTK2), the next wave of R&D is targeting substrate-selective inhibitors, bifunctional degrader strategies, and combination therapies with B-cell signaling inhibitors. PYK2 has emerged as a high-risk gene in GWAS for late-onset Alzheimer's disease, driving interest in neuroinflammatory pathways. In oncology, compensatory PYK2 activation limits first-generation FAK inhibitors, making selective PYK2 suppression critical for overcoming resistance in solid tumors and bone metastasis. Key indications include prostate cancer, breast cancer bone metastasis, osteoporosis, multiple sclerosis, autoimmune diseases, and Alzheimer's disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (ATP-competitive & selective) | Novartis, Biogen (historical), Pfizer, GSK, Academic consortia | Solid Tumors, Osteoporosis, Multiple Sclerosis | Selectivity Assay (Need PYK2 vs FAK Kinase Domains) |
| Small Molecule (Allosteric Inhibitor) | Nimbus Therapeutics (historical), Preclinical biotechs | Autoimmune Diseases, Neurodegeneration (AD) | Full-length Protein Conformation Assay (Need Lentivirus-based cellular systems) |
| Targeted Degrader (PROTAC) | Emerging Biotechs, Academic-Industry partnerships | Solid Tumors, Glioblastoma, Alzheimer's | Cell-Based Degradation Assay (Need Lentivirus ORF + Anti-PTK2B Antibody) |
| Biologic (targeting protein-protein interactions) | Emerging academic programs | Hematologic Malignancies | PPI Assay (Need high-purity recombinant domains) |